Compare IMKTA & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMKTA | NBTX |
|---|---|---|
| Founded | 1963 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1994 | 2018 |
| Metric | IMKTA | NBTX |
|---|---|---|
| Price | $85.75 | $39.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 110.2K | 103.7K |
| Earning Date | 05-11-2026 | 03-31-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $5,334,032,609.00 | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $59.27 | $6.09 |
| 52 Week High | $95.62 | $57.14 |
| Indicator | IMKTA | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 53.57 |
| Support Level | $82.53 | $38.89 |
| Resistance Level | $90.05 | $42.40 |
| Average True Range (ATR) | 2.52 | 2.49 |
| MACD | -0.63 | 0.10 |
| Stochastic Oscillator | 15.00 | 64.01 |
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.